Solventum SOLV NYSE · Healthcare · United States
$88.81 +0.21% +$0.19
Summary
42 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- It earns 17 USD a year on every 100 USD of invested capital.
What to watch
- Repaying its net debt would take 6.0 years of operating profit.
- Out of every 100 USD of revenue, only 1.9 USD is left as net profit.
- Revenue grew by only 0.8% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 96.7 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 0.8% a year over the last 3 years. For the next fiscal year analysts expect revenue to fall by 0.9%. Earnings per share grew by 4.5% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 46 USD
- Research and development 8.9 USD
- Sales and administration 21 USD
- Taxes and other 23 USD
- Net profit 1.9 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.5 USD
Out of every 100 USD of revenue, 1.9 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenIts debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 9
- Hold 2
- Sell 1
Today's price within the analysts' price targets
The average target of $91.13 is 2.6% above today's price. 75% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 100%
By region
- UNITED STATES 56%
- Non-US 44%
Product brings in 100% of revenue.
Segments in detail